GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

The pharmaceutical company citied promising pipeline developments and said cancer treatments drove above-expected growth.

Shares of British pharmaceutical giant GSK surged on Wednesday after the company raised its long-term sales forecast and ...

The pharmaceutical giant targets an increase in core operating profit of between 6% and 8% in 2025, after cancer treatments ...

Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than ...

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

Bearish flow noted in GSK (GSK) Pharma with 1,694 puts trading, or 4x expected. Most active are 2/7 weekly 34 puts and Jan-27 28 puts, with total volume in those strikes near 1,600 contracts.

In 2000, the Union for International Cancer Control (UICC) named Feb. | In 2000, the Union for International Cancer Control named Feb. 4 World Cancer Day, with a goal of raising awareness of cancer ...

Select listed pharma player including Pfizer, Novartis India, AstraZeneca Pharma and GSK Pharma shall be the beneficiaries of ...